Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Soft Tissue Neoplasms | 14 | 2022 | 1363 | 3.900 |
Why?
|
Salivary Gland Neoplasms | 16 | 2023 | 298 | 3.590 |
Why?
|
Myoepithelioma | 5 | 2020 | 43 | 2.860 |
Why?
|
Biopsy, Fine-Needle | 18 | 2022 | 1094 | 2.290 |
Why?
|
Immunohistochemistry | 30 | 2021 | 11366 | 2.150 |
Why?
|
RNA-Binding Protein EWS | 5 | 2023 | 216 | 2.030 |
Why?
|
Head and Neck Neoplasms | 15 | 2023 | 2736 | 1.850 |
Why?
|
Paranasal Sinus Neoplasms | 5 | 2022 | 234 | 1.790 |
Why?
|
Cytodiagnosis | 5 | 2019 | 435 | 1.680 |
Why?
|
Neurilemmoma | 4 | 2019 | 547 | 1.620 |
Why?
|
Epithelioid Cells | 3 | 2019 | 71 | 1.570 |
Why?
|
Nose Neoplasms | 4 | 2022 | 246 | 1.380 |
Why?
|
Liposarcoma | 4 | 2021 | 333 | 1.350 |
Why?
|
Gene Rearrangement | 7 | 2023 | 1179 | 1.320 |
Why?
|
Gene Fusion | 5 | 2021 | 371 | 1.320 |
Why?
|
Carcinoma | 9 | 2023 | 2375 | 1.250 |
Why?
|
Maxillary Sinus Neoplasms | 2 | 2018 | 40 | 1.210 |
Why?
|
Sarcoma | 7 | 2023 | 1897 | 1.140 |
Why?
|
Carcinoma, Acinar Cell | 3 | 2023 | 61 | 1.110 |
Why?
|
Diagnosis, Differential | 23 | 2021 | 12961 | 1.010 |
Why?
|
Oncogene Proteins, Fusion | 7 | 2023 | 1581 | 0.920 |
Why?
|
Receptors, Steroid | 2 | 2023 | 155 | 0.920 |
Why?
|
In Situ Hybridization, Fluorescence | 15 | 2023 | 2649 | 0.910 |
Why?
|
Neoplasms, Muscle Tissue | 2 | 2021 | 83 | 0.900 |
Why?
|
Papillomavirus Infections | 5 | 2022 | 1587 | 0.880 |
Why?
|
Carcinoma, Ductal | 2 | 2020 | 101 | 0.870 |
Why?
|
Nevus, Blue | 1 | 2022 | 38 | 0.850 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2018 | 871 | 0.830 |
Why?
|
Thyroid Gland | 6 | 2019 | 1173 | 0.790 |
Why?
|
Skin Neoplasms | 7 | 2024 | 5692 | 0.790 |
Why?
|
beta Catenin | 2 | 2016 | 1059 | 0.770 |
Why?
|
Receptors, Thyroid Hormone | 2 | 2023 | 202 | 0.760 |
Why?
|
Salivary Glands | 5 | 2023 | 229 | 0.760 |
Why?
|
Carcinoma, Adenoid Cystic | 6 | 2021 | 252 | 0.730 |
Why?
|
Sarcoma, Small Cell | 2 | 2018 | 22 | 0.710 |
Why?
|
Fibroma | 2 | 2020 | 212 | 0.710 |
Why?
|
Uveal Neoplasms | 1 | 2022 | 310 | 0.710 |
Why?
|
Homeodomain Proteins | 2 | 2019 | 2418 | 0.690 |
Why?
|
Neoplasms, Adipose Tissue | 1 | 2019 | 15 | 0.680 |
Why?
|
Rhabdomyoma | 2 | 2022 | 57 | 0.670 |
Why?
|
Mesenchymoma | 1 | 2019 | 47 | 0.670 |
Why?
|
Adenoma, Oxyphilic | 3 | 2019 | 143 | 0.640 |
Why?
|
Cytogenetic Analysis | 2 | 2018 | 295 | 0.630 |
Why?
|
Terminology as Topic | 3 | 2016 | 1547 | 0.630 |
Why?
|
Practice Guidelines as Topic | 6 | 2019 | 7282 | 0.630 |
Why?
|
Papillomaviridae | 4 | 2020 | 1119 | 0.620 |
Why?
|
Chondroma | 1 | 2018 | 58 | 0.620 |
Why?
|
Immunophenotyping | 4 | 2023 | 1880 | 0.610 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2019 | 191 | 0.600 |
Why?
|
In Situ Hybridization | 2 | 2019 | 1950 | 0.580 |
Why?
|
Skull Neoplasms | 1 | 2018 | 173 | 0.580 |
Why?
|
Facial Bones | 1 | 2018 | 201 | 0.570 |
Why?
|
Pelvic Neoplasms | 1 | 2018 | 254 | 0.560 |
Why?
|
Myofibroma | 1 | 2016 | 50 | 0.560 |
Why?
|
Fibrosarcoma | 1 | 2018 | 348 | 0.560 |
Why?
|
Pleural Effusion, Malignant | 2 | 2014 | 101 | 0.560 |
Why?
|
Thyroid Neoplasms | 7 | 2019 | 2282 | 0.550 |
Why?
|
Biopsy | 6 | 2020 | 6755 | 0.550 |
Why?
|
Hemangiopericytoma | 1 | 2016 | 77 | 0.540 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2018 | 514 | 0.540 |
Why?
|
World Health Organization | 3 | 2022 | 1318 | 0.540 |
Why?
|
Mouth Neoplasms | 4 | 2024 | 601 | 0.540 |
Why?
|
Carcinoma, Neuroendocrine | 3 | 2018 | 332 | 0.530 |
Why?
|
Neoplasms, Connective and Soft Tissue | 1 | 2015 | 37 | 0.520 |
Why?
|
Adenocarcinoma | 6 | 2020 | 6364 | 0.500 |
Why?
|
Hepatocyte Nuclear Factor 1-beta | 1 | 2015 | 94 | 0.500 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2019 | 3595 | 0.500 |
Why?
|
Pathology, Clinical | 1 | 2018 | 368 | 0.490 |
Why?
|
Nasal Cavity | 2 | 2022 | 313 | 0.490 |
Why?
|
Carcinoma, Squamous Cell | 9 | 2024 | 4034 | 0.490 |
Why?
|
S100 Proteins | 1 | 2015 | 259 | 0.480 |
Why?
|
Pericytes | 1 | 2016 | 293 | 0.470 |
Why?
|
Fetal Proteins | 1 | 2014 | 94 | 0.470 |
Why?
|
Adenoma, Pleomorphic | 3 | 2020 | 75 | 0.450 |
Why?
|
Thyroid Nodule | 3 | 2019 | 750 | 0.430 |
Why?
|
Gene Silencing | 1 | 2019 | 1539 | 0.430 |
Why?
|
Humans | 99 | 2024 | 744366 | 0.420 |
Why?
|
Aged | 42 | 2022 | 163288 | 0.420 |
Why?
|
Zebrafish Proteins | 1 | 2018 | 1005 | 0.420 |
Why?
|
Middle Aged | 47 | 2024 | 213390 | 0.410 |
Why?
|
Adult | 47 | 2023 | 214052 | 0.410 |
Why?
|
T-Box Domain Proteins | 1 | 2014 | 471 | 0.390 |
Why?
|
Young Adult | 25 | 2022 | 56429 | 0.380 |
Why?
|
Oropharyngeal Neoplasms | 4 | 2022 | 477 | 0.380 |
Why?
|
RNA, Viral | 1 | 2019 | 2901 | 0.380 |
Why?
|
Chordoma | 1 | 2014 | 359 | 0.370 |
Why?
|
Precancerous Conditions | 3 | 2024 | 975 | 0.370 |
Why?
|
DNA-Binding Proteins | 6 | 2023 | 9647 | 0.370 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2019 | 705 | 0.370 |
Why?
|
Male | 56 | 2024 | 350115 | 0.360 |
Why?
|
Aged, 80 and over | 25 | 2022 | 57776 | 0.360 |
Why?
|
Carcinoma, Papillary | 2 | 2018 | 783 | 0.350 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2020 | 2249 | 0.340 |
Why?
|
Mutation | 7 | 2022 | 29786 | 0.330 |
Why?
|
Bone Neoplasms | 3 | 2016 | 2530 | 0.330 |
Why?
|
Female | 54 | 2024 | 380193 | 0.330 |
Why?
|
Rhabdomyosarcoma | 1 | 2011 | 382 | 0.320 |
Why?
|
Nasopharyngeal Neoplasms | 3 | 2021 | 286 | 0.320 |
Why?
|
Sensitivity and Specificity | 7 | 2020 | 14723 | 0.310 |
Why?
|
Melanoma | 3 | 2022 | 5511 | 0.310 |
Why?
|
Mesothelioma | 1 | 2014 | 818 | 0.300 |
Why?
|
Genetic Predisposition to Disease | 7 | 2021 | 17446 | 0.300 |
Why?
|
Carcinoma, Small Cell | 3 | 2018 | 420 | 0.300 |
Why?
|
Testicular Neoplasms | 1 | 2013 | 806 | 0.300 |
Why?
|
Proto-Oncogene Proteins | 1 | 2019 | 4554 | 0.290 |
Why?
|
Hamartoma | 1 | 2009 | 238 | 0.290 |
Why?
|
Histones | 1 | 2017 | 2598 | 0.290 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2016 | 2043 | 0.280 |
Why?
|
Alphapapillomavirus | 1 | 2009 | 221 | 0.280 |
Why?
|
Paranasal Sinuses | 1 | 2009 | 250 | 0.280 |
Why?
|
HMGA2 Protein | 2 | 2017 | 123 | 0.280 |
Why?
|
Lipoma | 2 | 2019 | 334 | 0.270 |
Why?
|
Mitotic Index | 2 | 2018 | 172 | 0.270 |
Why?
|
Oxyphil Cells | 2 | 2019 | 57 | 0.270 |
Why?
|
Respiratory Mucosa | 1 | 2009 | 427 | 0.260 |
Why?
|
Adenoma | 1 | 2016 | 2174 | 0.260 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2021 | 602 | 0.260 |
Why?
|
Adolescent | 20 | 2022 | 85779 | 0.260 |
Why?
|
DNA Methylation | 2 | 2023 | 4285 | 0.250 |
Why?
|
Adamantinoma | 1 | 2023 | 9 | 0.240 |
Why?
|
Retroperitoneal Neoplasms | 2 | 2017 | 340 | 0.230 |
Why?
|
Predictive Value of Tests | 9 | 2021 | 15078 | 0.230 |
Why?
|
DNA Mutational Analysis | 5 | 2020 | 4185 | 0.220 |
Why?
|
Tumor Burden | 3 | 2021 | 1915 | 0.210 |
Why?
|
Cell Nucleus | 3 | 2016 | 2969 | 0.210 |
Why?
|
Genital Neoplasms, Male | 1 | 2022 | 74 | 0.210 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2022 | 56 | 0.210 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2022 | 100 | 0.200 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2011 | 2943 | 0.200 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 2850 | 0.190 |
Why?
|
Granuloma, Plasma Cell | 1 | 2021 | 84 | 0.190 |
Why?
|
Sarcoma, Kaposi | 1 | 2024 | 370 | 0.190 |
Why?
|
Reproducibility of Results | 6 | 2020 | 19905 | 0.190 |
Why?
|
Limbus Corneae | 1 | 2022 | 144 | 0.190 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2020 | 88 | 0.180 |
Why?
|
Carcinoma, Renal Cell | 1 | 2015 | 3143 | 0.180 |
Why?
|
Epithelium, Corneal | 1 | 2022 | 247 | 0.170 |
Why?
|
Oncogene Fusion | 1 | 2020 | 99 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2021 | 9240 | 0.170 |
Why?
|
Phenotype | 5 | 2021 | 16367 | 0.170 |
Why?
|
Submandibular Gland | 1 | 2019 | 86 | 0.170 |
Why?
|
Retinoblastoma-Binding Protein 1 | 1 | 2018 | 142 | 0.170 |
Why?
|
Transcription Factors | 3 | 2018 | 12207 | 0.170 |
Why?
|
Child | 12 | 2022 | 77709 | 0.170 |
Why?
|
Receptor, trkC | 1 | 2018 | 68 | 0.170 |
Why?
|
Synaptophysin | 1 | 2018 | 141 | 0.160 |
Why?
|
Neoadjuvant Therapy | 4 | 2023 | 2727 | 0.160 |
Why?
|
DNA, Viral | 2 | 2019 | 2227 | 0.160 |
Why?
|
Kidney Neoplasms | 1 | 2015 | 4262 | 0.160 |
Why?
|
Human papillomavirus 18 | 1 | 2018 | 128 | 0.150 |
Why?
|
Fibroma, Ossifying | 2 | 2020 | 19 | 0.150 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 2017 | 41 | 0.150 |
Why?
|
Carcinoma, Papillary, Follicular | 1 | 2018 | 60 | 0.150 |
Why?
|
Receptor, Notch1 | 2 | 2017 | 502 | 0.150 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 501 | 0.150 |
Why?
|
Prognosis | 8 | 2017 | 29060 | 0.150 |
Why?
|
Genital Neoplasms, Female | 1 | 2022 | 523 | 0.140 |
Why?
|
Laryngeal Neoplasms | 2 | 2018 | 512 | 0.140 |
Why?
|
Fibronectins | 1 | 2020 | 726 | 0.140 |
Why?
|
Cross Reactions | 1 | 2018 | 841 | 0.140 |
Why?
|
Antibody Specificity | 1 | 2018 | 1095 | 0.140 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2020 | 547 | 0.140 |
Why?
|
Retrospective Studies | 14 | 2022 | 77460 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-myb | 1 | 2016 | 78 | 0.130 |
Why?
|
Translocation, Genetic | 2 | 2018 | 1420 | 0.130 |
Why?
|
Dermatofibrosarcoma | 1 | 2016 | 63 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 381 | 0.130 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2016 | 111 | 0.130 |
Why?
|
Adrenal Glands | 1 | 2017 | 546 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2020 | 988 | 0.120 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2018 | 539 | 0.120 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2018 | 303 | 0.120 |
Why?
|
Ascitic Fluid | 1 | 2014 | 192 | 0.120 |
Why?
|
Neck | 1 | 2018 | 698 | 0.120 |
Why?
|
Cyclin D1 | 2 | 2016 | 463 | 0.120 |
Why?
|
Sclerosis | 1 | 2013 | 213 | 0.110 |
Why?
|
Neoplasm Invasiveness | 4 | 2017 | 3616 | 0.110 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2016 | 324 | 0.110 |
Why?
|
Immunoenzyme Techniques | 1 | 2016 | 1799 | 0.110 |
Why?
|
Neuroendocrine Tumors | 1 | 2018 | 594 | 0.110 |
Why?
|
Fas-Associated Death Domain Protein | 1 | 2012 | 27 | 0.110 |
Why?
|
Tissue Array Analysis | 2 | 2015 | 553 | 0.100 |
Why?
|
Adipocytes | 1 | 2019 | 1185 | 0.100 |
Why?
|
Pattern Recognition, Automated | 1 | 2018 | 1005 | 0.100 |
Why?
|
Feasibility Studies | 2 | 2019 | 5077 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2016 | 776 | 0.100 |
Why?
|
Calmodulin-Binding Proteins | 1 | 2013 | 250 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3207 | 0.100 |
Why?
|
Repressor Proteins | 2 | 2020 | 3024 | 0.100 |
Why?
|
Desmin | 1 | 2011 | 130 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 890 | 0.100 |
Why?
|
Chondrosarcoma | 1 | 2014 | 309 | 0.100 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2019 | 1660 | 0.100 |
Why?
|
Sequence Analysis, RNA | 1 | 2019 | 2012 | 0.100 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2018 | 2949 | 0.090 |
Why?
|
Lymphatic Metastasis | 1 | 2018 | 2924 | 0.090 |
Why?
|
Leiomyosarcoma | 1 | 2015 | 477 | 0.090 |
Why?
|
Respiratory Tract Neoplasms | 1 | 2010 | 57 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11525 | 0.090 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2014 | 507 | 0.090 |
Why?
|
Hashimoto Disease | 1 | 2011 | 98 | 0.090 |
Why?
|
Staining and Labeling | 1 | 2014 | 1101 | 0.090 |
Why?
|
Colon | 1 | 2017 | 1772 | 0.090 |
Why?
|
Receptor, erbB-2 | 2 | 2020 | 2417 | 0.080 |
Why?
|
Cohort Studies | 5 | 2019 | 40559 | 0.080 |
Why?
|
Neoplasm Metastasis | 3 | 2014 | 4851 | 0.080 |
Why?
|
Risk | 2 | 2011 | 9688 | 0.080 |
Why?
|
Biopsy, Needle | 1 | 2014 | 1641 | 0.080 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1692 | 0.080 |
Why?
|
Neoplasm Proteins | 2 | 2016 | 3707 | 0.070 |
Why?
|
Treatment Outcome | 5 | 2021 | 63107 | 0.060 |
Why?
|
Stomach Neoplasms | 1 | 2014 | 1332 | 0.060 |
Why?
|
Cell Differentiation | 3 | 2022 | 11486 | 0.060 |
Why?
|
Disease-Free Survival | 3 | 2021 | 6896 | 0.060 |
Why?
|
Survival Rate | 3 | 2017 | 12788 | 0.060 |
Why?
|
RNA-Binding Proteins | 1 | 2013 | 1903 | 0.060 |
Why?
|
Child, Preschool | 4 | 2022 | 41005 | 0.060 |
Why?
|
Antigen Presentation | 1 | 2009 | 1284 | 0.060 |
Why?
|
Nuclear Proteins | 1 | 2018 | 5856 | 0.060 |
Why?
|
Leukoplakia, Oral | 1 | 2024 | 73 | 0.060 |
Why?
|
Parotid Gland | 1 | 2024 | 168 | 0.060 |
Why?
|
Quality Improvement | 1 | 2018 | 3749 | 0.060 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2022 | 2016 | 0.060 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2009 | 1366 | 0.060 |
Why?
|
Neoplasm Staging | 2 | 2015 | 11031 | 0.050 |
Why?
|
Thyroidectomy | 2 | 2019 | 879 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7184 | 0.050 |
Why?
|
Databases, Factual | 2 | 2014 | 7730 | 0.050 |
Why?
|
Vimentin | 1 | 2022 | 262 | 0.050 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3590 | 0.050 |
Why?
|
Risk Assessment | 2 | 2019 | 23336 | 0.050 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13693 | 0.050 |
Why?
|
Esophageal Neoplasms | 1 | 2010 | 1585 | 0.050 |
Why?
|
Epithelial Cells | 2 | 2022 | 3690 | 0.040 |
Why?
|
Infant | 3 | 2022 | 35134 | 0.040 |
Why?
|
Nasopharynx | 1 | 2021 | 379 | 0.040 |
Why?
|
Mucins | 1 | 2022 | 564 | 0.040 |
Why?
|
International Agencies | 1 | 2019 | 240 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2019 | 318 | 0.040 |
Why?
|
Skull Base | 1 | 2021 | 306 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6539 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2019 | 220 | 0.040 |
Why?
|
HIV Infections | 1 | 2024 | 16715 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4479 | 0.040 |
Why?
|
Immunotherapy | 2 | 2024 | 4446 | 0.040 |
Why?
|
United States | 3 | 2021 | 69872 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2020 | 11126 | 0.040 |
Why?
|
Gadolinium | 1 | 2021 | 952 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 53 | 0.030 |
Why?
|
Breast Neoplasms | 2 | 2022 | 20824 | 0.030 |
Why?
|
Adrenalectomy | 1 | 2017 | 341 | 0.030 |
Why?
|
Head | 1 | 2021 | 880 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2016 | 251 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2021 | 1275 | 0.030 |
Why?
|
Canada | 1 | 2020 | 2065 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1038 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1970 | 0.030 |
Why?
|
Cornea | 1 | 2022 | 1524 | 0.030 |
Why?
|
Health Facilities | 1 | 2019 | 572 | 0.030 |
Why?
|
Observer Variation | 1 | 2020 | 2593 | 0.030 |
Why?
|
Medical Records | 1 | 2019 | 1413 | 0.030 |
Why?
|
Europe | 1 | 2020 | 3338 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2021 | 9445 | 0.030 |
Why?
|
Risk Factors | 1 | 2020 | 72296 | 0.030 |
Why?
|
Base Sequence | 2 | 2016 | 12797 | 0.030 |
Why?
|
Colectomy | 1 | 2017 | 680 | 0.030 |
Why?
|
Metaphase | 1 | 2012 | 151 | 0.030 |
Why?
|
Chromosome Breakage | 1 | 2012 | 173 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2022 | 2645 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3480 | 0.030 |
Why?
|
Time Factors | 1 | 2013 | 40075 | 0.030 |
Why?
|
Nephrectomy | 1 | 2017 | 1050 | 0.030 |
Why?
|
Hospitals, Teaching | 1 | 2016 | 1180 | 0.020 |
Why?
|
Androgen Antagonists | 1 | 2020 | 1377 | 0.020 |
Why?
|
Paraffin Embedding | 1 | 2012 | 299 | 0.020 |
Why?
|
Cell Shape | 1 | 2012 | 375 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2018 | 8432 | 0.020 |
Why?
|
Hypopharyngeal Neoplasms | 1 | 2010 | 50 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2011 | 588 | 0.020 |
Why?
|
Chromosomes, Human | 1 | 2012 | 457 | 0.020 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39052 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 1 | 2016 | 1142 | 0.020 |
Why?
|
Prospective Studies | 3 | 2020 | 53290 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4398 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2133 | 0.020 |
Why?
|
Fibroblasts | 1 | 2020 | 4162 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1257 | 0.020 |
Why?
|
Stem Cells | 1 | 2022 | 3567 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2011 | 980 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2017 | 10483 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7294 | 0.020 |
Why?
|
Contrast Media | 1 | 2021 | 5300 | 0.020 |
Why?
|
Chromatin | 1 | 2020 | 2933 | 0.020 |
Why?
|
Antibodies, Monoclonal | 2 | 2019 | 9274 | 0.020 |
Why?
|
Urothelium | 1 | 2009 | 277 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2022 | 19233 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3508 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3921 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2022 | 6234 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10252 | 0.020 |
Why?
|
Boston | 1 | 2016 | 9312 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2012 | 6171 | 0.010 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2009 | 808 | 0.010 |
Why?
|
Lymphoma | 1 | 2011 | 1877 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 25628 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25039 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2011 | 5974 | 0.010 |
Why?
|
Recurrence | 1 | 2012 | 8340 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2012 | 18111 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 13882 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 20952 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2010 | 8642 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 35425 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2012 | 15520 | 0.010 |
Why?
|
Signal Transduction | 1 | 2016 | 23404 | 0.010 |
Why?
|